PMLT21061 / APEC1621K / Mullen
Basic Study Information
Purpose:Location: University of Rochester
This phase II Pediatric MATCH trial studies how well ivosidenib works in treating
patients with solid tumors that have spread to other places in the body (advanced),
lymphoma, or histiocytic disorders that have IDH1 genetic alterations (mutations).
Ivosidenib may block the growth of cancer cells that have specific genetic changes
in an important signaling pathway called the IDH pathway.
Lead Researcher (Principal Investigator)
Study Contact Information
Study Contact: Clinical Trials Office
Study Location: Wilmot Cancer Institute, University of Rochester Medical Center
Study Email: WCICTOResearch@urmc.rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search